Journal Article
. 2018 Jan;169(1).
doi: 10.1007/s10549-017-4646-1.

Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative

Lu Zhang 1 Qingzhao Yu 2 Xiao-Cheng Wu 1 Mei-Chin Hsieh 1 Michelle Loch 3 Vivien W Chen 1 Elizabeth Fontham 1 Tekeda Ferguson 4 
  • PMID: 29368311
  •     36 References
  •     7 citations


Purpose: To investigate the impact of chemotherapy relative dose intensity (RDI) on cause-specific and overall survival for stage I-III breast cancer: estrogen receptor or progesterone receptor positive, human epidermal-growth factor receptor negative (ER+/PR+ and HER2-) vs. triple-negative (TNBC) and to identify the optimal RDI cut-off points in these two patient populations.

Methods: Data were collected by the Louisiana Tumor Registry for two CDC-funded projects. Women diagnosed with stage I-III ER+/PR+, HER2- breast cancer, or TNBC in 2011 with complete information on RDI were included. Five RDI cut-off points (95, 90, 85, 80, and 75%) were evaluated on cause-specific and overall survival, adjusting for multiple demographic variables, tumor characteristics, comorbidity, use of granulocyte-growth factor/cytokines, chemotherapy delay, chemotherapy regimens, and use of hormone therapy. Cox proportional hazards models and Kaplan-Meier survival curves were estimated and adjusted by stabilized inverse probability treatment weighting (IPTW) of propensity score.

Results: Of 494 ER+/PR+, HER2- patients and 180 TNBC patients, RDI < 85% accounted for 30.4 and 27.8%, respectively. Among ER+/PR+, HER2- patients, 85% was the only cut-off point at which the low RDI was significantly associated with worse overall survival (HR = 1.93; 95% CI 1.09-3.40). Among TNBC patients, 75% was the cut-off point at which the high RDI was associated with better cause-specific (HR = 2.64; 95% CI 1.09, 6.38) and overall survival (HR = 2.39; 95% CI 1.04-5.51).

Conclusions: Higher RDI of chemotherapy is associated with better survival for ER+/PR+, HER2- patients and TNBC patients. To optimize survival benefits, RDI should be maintained ≥ 85% in ER+/PR+, HER2- patients, and ≥ 75% in TNBC patients.

Keywords: Breast cancer; Chemotherapy; Hormone receptor positive, Triple-negative; Relative dose intensity.

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
Michelle Shayne, Jeffrey Crawford, +3 authors, ANC Study Group.
Breast Cancer Res Treat, 2006 May 18; 100(3). PMID: 16705366
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Gary H Lyman, David C Dale, +2 authors, Jeffrey Crawford.
Breast Cancer Res Treat, 2013 Jun 19; 139(3). PMID: 23771731
A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study.
Peter C Austin, Paul Grootendorst, Geoffrey M Anderson.
Stat Med, 2006 May 19; 26(4). PMID: 16708349
Highly Cited.
Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.
Hee Jin Lee, In Hye Song, +8 authors, Gyungyub Gong.
Ann Surg Oncol, 2014 Sep 07; 22(2). PMID: 25192679
Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy.
Jia-Qi Yuan, Shou-Man Wang, +13 authors, Fei-Yu Chen.
Breast Cancer Res Treat, 2015 May 10; 151(2). PMID: 25956059
Enhancing cancer registry data for comparative effectiveness research (CER) project: overview and methodology.
Vivien W Chen, Christie R Eheman, +13 authors, Kevin B Zhang.
J Registry Manag, 2014 Nov 25; 41(3). PMID: 25419602    Free PMC article.
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
Sibylle Loibl, Tomas Skacel, +5 authors, Gunter von Minckwitz.
BMC Cancer, 2011 Apr 14; 11. PMID: 21486442    Free PMC article.
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.
G Bonadonna, P Valagussa, +2 authors, C Brambilla.
N Engl J Med, 1995 Apr 06; 332(14). PMID: 7877646
Highly Cited.
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.
Neelima Denduluri, Debra A Patt, +10 authors, Gary H Lyman.
J Natl Compr Canc Netw, 2015 Nov 11; 13(11). PMID: 26553767
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, +34 authors, Gunter von Minckwitz.
Lancet, 2014 Feb 18; 384(9938). PMID: 24529560
Highly Cited. Review.
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
Hude Quan, Vijaya Sundararajan, +7 authors, William A Ghali.
Med Care, 2005 Oct 15; 43(11). PMID: 16224307
Highly Cited.
Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.
W Hryniuk, M N Levine.
J Clin Oncol, 1986 Aug 01; 4(8). PMID: 3525765
Highly Cited.
Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
B Fisher, J H Jeong, +4 authors, N Wolmark.
J Natl Cancer Inst Monogr, 2002 Jan 05; (30). PMID: 11773294
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
Gary H Lyman, David C Dale, Jeffrey Crawford.
J Clin Oncol, 2003 Dec 16; 21(24). PMID: 14673039
Highly Cited.
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.
Peter C Austin, Elizabeth A Stuart.
Stat Med, 2015 Aug 05; 34(28). PMID: 26238958    Free PMC article.
Highly Cited. Systematic Review.
Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study.
E G Mansour, R Gray, +4 authors, G Falkson.
J Clin Oncol, 1998 Nov 17; 16(11). PMID: 9817265
Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
Isabel Chirivella, Begoña Bermejo, +7 authors, Ana Lluch.
Breast Cancer Res Treat, 2008 May 09; 114(3). PMID: 18463977
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
B Fisher, J Dignam, +10 authors, R G Margolese.
J Natl Cancer Inst, 1997 Dec 09; 89(22). PMID: 9390536
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes.
Peter C Austin, Elizabeth A Stuart.
Stat Methods Med Res, 2015 May 03; 26(4). PMID: 25934643    Free PMC article.
Impact of chemotherapy dose intensity on cancer patient outcomes.
Gary H Lyman.
J Natl Compr Canc Netw, 2009 Jan 30; 7(1). PMID: 19176210
Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.
Marco Colleoni, Sigui Li, +5 authors, International Breast Cancer Study Group.
Lancet, 2005 Sep 27; 366(9491). PMID: 16182899
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H M Kuerer, L A Newman, +13 authors, S E Singletary.
J Clin Oncol, 1999 Mar 18; 17(2). PMID: 10080586
Highly Cited.
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.
D R Budman, D A Berry, +8 authors, E Frei.
J Natl Cancer Inst, 1998 Aug 27; 90(16). PMID: 9719081
Highly Cited.
The calculation of actual or received dose intensity: a comparison of published methods.
D L Longo, P L Duffey, +3 authors, R C Young.
J Clin Oncol, 1991 Nov 11; 9(11). PMID: 1941063
Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice.
Derek Weycker, Rich Barron, +2 authors, Gary H Lyman.
Breast Cancer Res Treat, 2012 Jan 25; 133(1). PMID: 22270932
Chemotherapy dose intensity and quality cancer care.
Gary H Lyman.
Oncology (Williston Park), 2007 Mar 21; 20(14 Suppl 9). PMID: 17370925
Publication of tumor marker research results: the necessity for complete and transparent reporting.
Lisa M McShane, Daniel F Hayes.
J Clin Oncol, 2012 Oct 17; 30(34). PMID: 23071235    Free PMC article.
Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression.
Hyeong-Gon Moon, Seock-Ah Im, +8 authors, Dong-Young Noh.
Breast Cancer Res Treat, 2012 Jul 04; 134(3). PMID: 22752292
Weight trimming and propensity score weighting.
Brian K Lee, Justin Lessler, Elizabeth A Stuart.
PLoS One, 2011 Apr 13; 6(3). PMID: 21483818    Free PMC article.
A review of relative dose intensity and survival in patients with metastatic solid tumors.
Laura J Havrilesky, Maureen Reiner, +2 authors, Jeffrey Crawford.
Crit Rev Oncol Hematol, 2014 Dec 03; 93(3). PMID: 25459671
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Molecular markers for breast cancer diagnosis, prognosis and targeted therapy.
Julie E Lang, Julie S Wecsler, Michael F Press, Debasish Tripathy.
J Surg Oncol, 2014 Aug 06; 111(1). PMID: 25091830
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.
Adedayo A Onitilo, Jessica M Engel, Robert T Greenlee, Bickol N Mukesh.
Clin Med Res, 2009 Jul 04; 7(1-2). PMID: 19574486    Free PMC article.
Highly Cited.
Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals.
Stanley Xu, Colleen Ross, +3 authors, David Smith.
Value Health, 2009 Nov 17; 13(2). PMID: 19912596    Free PMC article.
Impact of relative dose intensity on bone marrow suppression induced by S-1: retrospective observational study.
Toshinori Hirai, Ryuichi Ogawa, Ryosuke Yamaga, Toshimasa Itoh.
J Pharm Health Care Sci, 2018 Dec 14; 4. PMID: 30524750    Free PMC article.
Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer.
Elizabeth M Cespedes Feliciano, Wendy Y Chen, +6 authors, Bette J Caan.
JAMA Oncol, 2019 Dec 06; 6(2). PMID: 31804676    Free PMC article.
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
Lauren A Marcath, Kelley M Kidwell, +10 authors, Daniel L Hertz.
Br J Clin Pharmacol, 2019 Dec 12; 86(5). PMID: 31823378    Free PMC article.
Hyaluronan Metabolism is Associated with DNA Repair Genes in Breast and Colorectal Cancer. Screening of Potential Progression Markers Using qPCR.
Ina Sevic, Fiorella Mercedes Spinelli, +7 authors, Laura Alaniz.
Biomedicines, 2020 Jul 03; 8(7). PMID: 32610620    Free PMC article.
The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource-Stratified Phased Implementation: Methods and overview.
Catherine Duggan, Allison Dvaladze, +13 authors, Benjamin O Anderson.
Cancer, 2020 Apr 30; 126 Suppl 10. PMID: 32348573    Free PMC article.
Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial.
O Abdel-Rahman.
Clin Transl Oncol, 2018 Jun 30; 21(2). PMID: 29956074
Identification of long non‑coding RNA‑mediated transcriptional dysregulation triplets reveals global patterns and prognostic biomarkers for ER+/PR+, HER2‑ and triple negative breast cancer.
Zhengwei Du, Wei Gao, +5 authors, Wenbin Guo.
Int J Mol Med, 2019 Jul 02; 44(3). PMID: 31257479    Free PMC article.